GlassScriptPhysician profile
David M Sullivan
NPI 1386751329
$5,737.67
in general payments reported to CMS, 2019-2025
37 companies · $16.22 in 2025
The $16.22 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,532 · 2020: $323 · 2021: $786 · 2022: $1,623 · 2023: $1,417 · 2024: $41.24 · 2025: $16.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $730.63 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Abbvie INC. | $719.63 | 2019-2023 | Ubrelvy, Qulipta, Viberzi |
| Pfizer INC. | $547.74 | 2019-2024 | |
| Lilly USA, LLC | $401.25 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $361.75 | 2019-2023 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $357.32 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $350.32 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $273.97 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $190.71 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.74 | 2021-2023 | Ninlaro |
| Allergan, INC. | $142.12 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.07 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $136.31 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $115.83 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.11 | 2021-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.